Your browser doesn't support javascript.
loading
Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies.
Moors, Tim E; Mona, Daniel; Luehe, Stefan; Duran-Pacheco, Gonzalo; Spycher, Liz; Mundigl, Olaf; Kaluza, Klaus; Huber, Sylwia; Hug, Melanie N; Kremer, Thomas; Ritter, Mirko; Dziadek, Sebastian; Dernick, Gregor; van de Berg, Wilma D J; Britschgi, Markus.
Afiliación
  • Moors TE; Section Clinical Neuroanatomy and Biobanking, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije University Amsterdam, Boelelaan 1108, 1081HZ, Amsterdam, The Netherlands.
  • Mona D; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Rd, MA, 02115, Boston, USA.
  • Luehe S; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Duran-Pacheco G; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Spycher L; Roche Pharma Research and Early Development; Pharmaceutical Sciences, Biostatistics, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Mundigl O; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Kaluza K; Roche Pharma Research and Early Development, Therapeutic Modalities; Large Molecule Research, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
  • Huber S; Roche Pharma Research and Early Development, Therapeutic Modalities; Large Molecule Research, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
  • Hug MN; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Kremer T; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Ritter M; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Dziadek S; Research & Development Roche Diagnostics Solutions, Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany.
  • Dernick G; Roche Pharma Research and Early Development; Oncology Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • van de Berg WDJ; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Britschgi M; Section Clinical Neuroanatomy and Biobanking, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije University Amsterdam, Boelelaan 1108, 1081HZ, Amsterdam, The Netherlands. wdj.vandeberg@amsterdamumc.nl.
Acta Neuropathol Commun ; 10(1): 82, 2022 06 03.
Article en En | MEDLINE | ID: mdl-35659116
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Atrofia de Múltiples Sistemas / Enfermedad por Cuerpos de Lewy / Sinucleinopatías Idioma: En Revista: Acta Neuropathol Commun Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Atrofia de Múltiples Sistemas / Enfermedad por Cuerpos de Lewy / Sinucleinopatías Idioma: En Revista: Acta Neuropathol Commun Año: 2022 Tipo del documento: Article